Drug Action
Streptozocin is an antibiotic antineoplastic nitrosourea.
PDF page 970
Loading InternPractice…
Drug reference
Streptozocin is an antibiotic antineoplastic nitrosourea.
PDF page 970
Neuroendocrine tumours of pancreatic origin (specialist use only) ▶BY INTRAVENOUS INFUSION ▶Adult: (consult product literature)
PDF page 970
Antiemetic pre-medication recommended. avoid extravasation (risk of tissue necrosis). elderly. hyperhydration required (consult product literature)
PDF page 970
→Appendix 1: streptozocin
PDF page 970
▶Common or very common Acute kidney injury. diarrhoea. nausea. nephropathy. renal tubular injury. urinary disorder. urine abnormalities. vomiting ▶Frequency not known Confusion. depression. extravasation necrosis. fever. glucose tolerance impaired. hepatotoxicity. hypoalbuminaemia. lethargy
PDF page 970
Manufacturer advises women of childbearing potential should use effective contraception during treatment and for 30 days after last treatment; male patients should use effective contraception during treatment and for 90 days after last treatment if their partner is of childbearing potential. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 970
Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 970
Manufacturer advises avoid—no information available.
PDF page 970
Manufacturer advises caution. Dose adjustments Manufacturer advises consider dose reduction.
PDF page 970
Manufacturer advises caution— evaluate benefit/risk ratio if eGFR 30–45 mL/minute/1.73 m2; avoid if eGFR less than 30 mL/minute/1.73 m2. Dose adjustments Manufacturer advises reduce dose if eGFR 46–60 mL/minute/1.73 m2—consult product literature.
PDF page 970
▶Manufacturer advises monitor renal function (plasma creatinine and eGFR derived from the MDRD formula) immediately before treatment initiation and 2 weeks after each course of therapy; proteinuria and serum electrolytes should also be monitored before treatment initiation and 2–4 weeks after the last cycle of treatment. ▶Manufacturer advises monitor liver function tests, blood glucose levels and complete blood counts regularly. l HANDLING AND STORAGE Manufacturer advises store in a refrigerator (2–8°C) and protect from light—consult product literature for storage conditions after reconstitution and dilution.
PDF pages 970, 971
There can be variation in the licensing of different medicines containing the same drug. Powder for solution for infusion ▶Zanosar (Intrapharm Laboratories Ltd) Streptozocin 1 gram Zanosar 1g powder for concentrate for solution for infusion vials | 1 vial P £570.00
PDF page 971
(consult product literature)
First-line fragment. Read the complete Indications and Dose section above.
PDF page 970